Aug 25 U.S. government officials say they will
appeal a U.S. District Court injunction that stops new federal
funding of human embryonic stem cell research.
The ruling has no direct effect on researchers or companies
working with private funds, but government funding often
kick-starts the most basic, and risky biological work.
Scientists are working to use them to repair severed spinal
cords, regenerate brain cells lost in Parkinson's disease and
restore the tissue destroyed by juvenile diabetes.
Below is a partial list companies working to develop both
adult and embryonic stem cells as therapies:
* Geron Corp. (GERN.O) recently received U.S. Food and
Drug Administration approval to start testing its experimental
human embryonic stem cell therapy in people with new spinal
cord injuries -- the first trial of the controversial cells in
* StemCells Inc. STEM.O recently said its human neural
stem cells helped improve movement in mice being treated for
spinal injuries. The Palo Alto, California-based company plans
to start human trials in 2011.
* Advanced Cell Technology Inc ACTC.OB recently received
orphan drug status from the FDA for retinal stem cells to treat
Stargardt's Macular Dystrophy, which can lead to blindness.
* Neuralstem Inc. CUR.A said on Wednesday it has filed an
investigational new drug application with the FDA to begin a
Phase 1 safety clinical trial for chronic spinal cord injury
with its spinal cord stem cells. It is also testing its cells
in patients with amyotrophic lateral sclerosis, also known as
ALS or Lou Gehrig's disease.
* Aastrom Biosciences Inc. ASTMD.O is working on ways to
take a patient's own cells and use them to treat heart disease.
These are in advanced trials in patients.
* Thermogenesis Corp. (KOOL.O) supplies products and
services that process and store adult stem cells. The company
recently cut its workforce by 10 percent to lower expenses.
* Osiris Therapeutics Inc. (OSIR.O), is testing so-called
adult stem cells taken from the bone marrow in patients with
Crohn's disease and graft versus host disease.
* Cytori Therapeutics Inc. (CYTX.O) uses its Celution
system to take stem and regenerative cells from a patient's own
fat tissue to form a fat graft to reconstruct and repair breast
and soft tissue. It is not yet available in the United States.
Its StemSource product line is sold globally for cell banking
and research applications.
* ReNeuron Group Plc (RQE.L) reported positive mouse data
with its REN009 stem cell therapy for peripheral arterial
disease in diabetes. It hopes to apply to start trials in
people next year.
* Aldagen Inc, a private company, announced results last
year from a Phase 1 clinical trial of ALD-201, a stem cell
treatment for heart failure. Many companies are working to find
ways to use stem cells to regenerate damaged heart tissue.
* Celgene Corp (CELG.O), better known for blood cancer
treatments, has an experimental stem cell treatment for Crohn's
disease in phase 1 clinical trials.
* International Stem Cell Corporation ISCO.OB in
California is trying to make human stem cells via a process
known as parthenogenesis, in which an unfertilized egg begins
to divide and grow as if it were fertilized by sperm. It
positions its potential products as alternatives to embryonic
(Reporting by Toni Clarke in Boston; Editing by Maggie Fox)